|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
University Hospital, Basel, Switzerland University Hospital, Bonn |
|---|---|
| Information provided by: | University Hospital, Basel, Switzerland |
| ClinicalTrials.gov Identifier: | NCT00691340 |
Purpose
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier studies the investigators could demonstrate that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential mRNA expression and an increased fragmentation of the DNA. Such alterations point out a relationship between cellular stress and apoptotic events.
Based on the results of mRNA-expression the investigators also expect alterations on the protein level.
This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways.
Thus, the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with samples from healthy controls. In addition, they will also be compared with samples from patients with Alzheimer's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as positive controls in this study.
| Condition |
|---|
|
Alzheimer's Disease Glaucoma |
| Study Type: | Observational |
| Study Design: | Case-Only, Prospective |
| Official Title: | Systematic Characterization of the Cellular Proteome From Human Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease |
plasma
| Estimated Enrollment: | 80 |
| Study Start Date: | May 2008 |
| Estimated Study Completion Date: | September 2009 |
| Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
Control 1 (young subjects)
|
|
2
Control 2 (old subjects)
|
|
3
Glaucoma patients
|
|
4
Alzheimer patients
|
Hypothesis:
Differences in the proteome concerning cell death pathways of glaucoma patients correspond to the differences in the mRNA expression of these patients.
Specific aims:
Characterization of the cellular proteome from human leukocytes of glaucoma patients compared to healthy controls and patients with Alzheimer's disease.
Background:
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier studies we could demonstrate that this cell death is reflected in circulating leukocytes by different parameters, like differential mRNA expression, and an increased fragmentation of the DNA. The differences in mRNA expression indicate a close relationship to cellular stress conditions and apoptotic events: increased mRNA expression was detected for p53, 20S proteasome alpha subunit, ABC1 transporter, p21(WAF1/CIP1), 14-3-3 sigma factor, MMP-9 and MMP-14, and TIMP-1.
Based on the assumption that glaucoma patients may differ on the level of their expression for these mRNAs, we expect that similar differences should exist at the protein level.
This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Glaucoma patients Alzheimer's patients
Inclusion Criteria:
Exclusion Criteria:
Any history of:
Contacts and Locations| Contact: Stephan A Fraenkl, MD | +41-61-2658645 | sfraenkl@uhbs.ch |
| Switzerland, BS | |
| University Hospital Basel, Eye Clinic | Recruiting |
| Basel, BS, Switzerland, 4031 | |
| Contact: Selim Orgül, MD +41-61-2658633 orguels@uhbs.ch | |
| Study Director: | Selim Orguel, MD | University Hospital, Basel, Switzerland |
More Information
| Responsible Party: | University Hospital, Basel, Switzerland ( Selim Orgül, MD ) |
| Study ID Numbers: | 075-WUK-2008-002 |
| Study First Received: | June 3, 2008 |
| Last Updated: | June 4, 2008 |
| ClinicalTrials.gov Identifier: | NCT00691340 |
| Health Authority: | Switzerland: Swissmedic |
|
POAG Alzheimer's disease cellular proteome |
human leucocytes vasospasm Healthy subjects |
|
Eye Diseases Alzheimer Disease Central Nervous System Diseases Healthy Brain Diseases Neurodegenerative Diseases Cognition Disorders |
Delirium, Dementia, Amnestic, Cognitive Disorders Glaucoma Mental Disorders Dementia Delirium Ocular Hypertension Hypertension |
|
Nervous System Diseases Tauopathies |
